Skip to main content
Premium Trial:

Request an Annual Quote

Philip Leder, Paul Billings, Geoffrey Duyk, Frank McCormick, Greg Plowman, Michael Morrissey, Jeffrey Latts, George Scangos


Philip Leder, head of the department of genetics at Harvard Medical School, has been elected to the board of directors at Schering-Plough. He will begin Nov. 1.

Leder is also a senior investigator of the Howard Hughes Medical Institute, and an honorary trustee of the Massachusetts General Hospital, chairman of the Board of the Charles A. Revson Foundation, a trustee of the Foundation for Advanced Education in the Sciences, and the Hadassah Medical Organization.

Paul Billings has been named vice president and national director of genetics and genomics at Burlington, NC-based Laboratory Corporation of America Holdings.

Billings, who will head efforts to provide genomic and genetic tests and services at the company, comes to LabCorp from WIPRO, where he was a vice president for life sciences and clinical affairs at WIPRO HealthSciences, its subsidiary. He has also held clinical faculty appointments at Harvard Medical School, the University of California at San Francisco, and Stanford.

Geoffrey Duyk will step down as president of R&D and CSO of Exelixis at the end of the year “in order to pursue other professional opportunities,” Exelixis said in a statement. Frank McCormick, a member of the company’s board of directors and director of the University of California, San Francisco Comprehensive Cancer Center, will assume a senior advisory role in the company’s R&D organization. Additionally, Greg Plowman, Michael Morrissey, and Jeffrey Latts will continue in their current respective roles of senior vice president of research, senior vice president of discovery research, and chief medical officer. They and McCormick will work with CEO George Scangos to help transition Exelixis’ R&D organization.

Duyk joined Exelixis in April 1997 from Millennium Pharmaceuticals, where he was one of the founding scientific staff and vice president of genomics. McCormick joined Exelixis’ board in July 2003. Before joining UCSF, he was the founder and CSO of Onyx Pharmaceuticals. Before that, he was vice president of research at Chiron, and vice president of research at Cetus.


Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.